International Journal of Transgender Health最新文献

Background: High rates of pelvic pain have been reported in trans individuals on testosterone, but the pathophysiology of pain and the potential role of testosterone are unclear.

Aims: The aim of this exploratory study was to determine whether the proportion of pelvic pain in trans adolescents is different among those on testosterone therapy compared to those who are not. Secondary objectives were to determine the characteristics, potential contributing factors, impact, and treatment of pelvic pain in trans adolescents.

Methods: An online cross-sectional study about pelvic pain was conducted among trans individuals assigned female at birth, aged 12 and over, and who had sought care at our institution since 2017.

Results: Among 102 participants, 79 (77.5%) reported having experienced pelvic pain over the last 6 months. The proportion of individuals who reported pelvic pain was lower in individuals on testosterone (n = 43/62, 69.4%) compared to those not on testosterone (n = 36/40, 90%), with a difference in proportion of -20.6% (95% CI -35.4 to -5.9%, p = 0.006). Half of participants reported school or work absenteeism and two thirds missed extracurricular activities because of pelvic pain. A wide range of treatment options were used, with variable rates of reported effectiveness.

Conclusion: Pelvic pain is frequently reported by trans adolescents. This exploratory study found a lower proportion of pelvic pain in trans adolescents using testosterone therapy compared to those who were not. Nevertheless, this study was limited by a small number of participants, its cross-sectional nature, and the risk of recruitment bias, thus limiting its generalizability. Longitudinal studies are required to better understand the development and evolution of pelvic pain in trans adolescents.

Background: Transgender and Allogender Individuals Assigned Female At Birth (transgender and allogender individuals AFAB) face obstacles and inequalities in healthcare access compared to cisgender individuals. These challenges derive from social stigma, knowledge gaps, and scarcity of professionals trained to address the specific needs of these populations. Since transgender and allogender individuals AFAB may retain breast tissue and a cervix, they require integral sexual health care, including early detection of cervical and breast cancer. However, specific barriers and guidelines for early detection in these populations remain undefined. Aim: To review literature on early cervical and breast cancer screening in transgender and allogender individuals AFAB and identify research gaps. Methods: This scoping review followed the Joanna Briggs Institute methodology, and the report adhered to the PRISMA-ScR checklist. Searches were conducted across seven databases, including peer-reviewed and grey literature. Study selection was conducted independently by two reviewers using RAYYAN software. Data from selected studies were analyzed qualitatively by thematic analysis. Results: Out of 709 identified studies, 61 articles and 5 grey literature documents were included in the review dataset. The majority of these were published in 2020 (24.2%), originating from the USA (72.7%), and employing a cross-sectional design (39.4%). From the thematic analysis, six main themes were identified for cervical cancer and five for breast cancer. Among these, five themes were common to both types of cancer: screening rates, barriers, strategies, guidelines, and the role of healthcare professionals. The theme of knowledge, beliefs, and attitudes was found solely in the context of cervical cancer. Conclusions: The evidence indicates that healthcare attention for cervical and breast cancer remains predominantly linked to sex assigned at birth, neglecting gender implications for transgender and allogender AFAB populations. The existing disparities in detection rates and access present a significant challenge in gynecological care for these groups.